Alibaba led a CNY560m (~USD88m) Series D for Creative Biosciences, a China-based early-stage cancer screening solutions company, with participation from Huaxing Growth Capital, Co-Stone Asset Management, ABC International and Henglu Asset Management, and follow-on from IDG Capital. Read more